Most Read Articles
Roshini Claire Anthony, 28 Apr 2020

Three studies initially scheduled for presentation at AAAAI 2020 demonstrated that epinephrine delivered intranasally was more rapidly absorbed and led to greater haemodynamic response compared with epinephrine delivered intramuscularly.

Roshini Claire Anthony, 19 Dec 2019

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.

Product Highlight - Benlysta

20 Dec 2019
Adding BENLYSTA to standard therapy:
• Superior reduction in SLE disease activity1*†‡
• Reduction in corticosteroid dose in patients on >7.5 mg/day at baseline1#
• Severe flare risk reduction by 50%1
• Significant improvement in fatigue as early as Week 82^
• Rates of adverse events were similar between BENLYSTA and placebo1-3*

Remarks: * Defined as positive anti-dsDNA (≥30 IU/mL) and low C3 and/or C4 complement. Standard therapies permitted, alone or in combination: corticosteroids, immunosuppressants, antimalarials, and NSAIDs. BLISS-52 and BLISS-76 pooled data. # Reduction to ≤7.5 mg/day: 24.6% vs 15.0% (p = 0.035).
^ FACIT-Fatigue score improvement at Week 52: 4.07 vs 1.80 (p = 0.004).

References:
1. Benlysta SC Prescribing Information version GDS15.
2. van Vollenhoven RF, Petri MA, Cervera R, et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis. 2012;71:1343-1349.
3. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9767):721-731.


Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacy - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 28 Apr 2020

Three studies initially scheduled for presentation at AAAAI 2020 demonstrated that epinephrine delivered intranasally was more rapidly absorbed and led to greater haemodynamic response compared with epinephrine delivered intramuscularly.

Roshini Claire Anthony, 19 Dec 2019

First-line treatment with the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) dacomitinib demonstrated persistent survival benefit in patients with EGFR-positive advanced non-small cell lung cancer (NSCLC), according to updated results from the phase III ARCHER 1050* trial.